Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial

Arthritis Rheum. 2006 Feb;54(2):678-81. doi: 10.1002/art.21563.
No abstract available

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adalimumab
  • Adult
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents / therapeutic use*
  • Female
  • Humans
  • Injections, Subcutaneous
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Pilot Projects
  • Sacroiliac Joint / drug effects
  • Sacroiliac Joint / pathology
  • Severity of Illness Index
  • Spine / drug effects
  • Spine / pathology*
  • Spine / physiopathology
  • Spondylitis, Ankylosing / drug therapy*
  • Spondylitis, Ankylosing / pathology
  • Spondylitis, Ankylosing / physiopathology
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / immunology*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha
  • Adalimumab